Lycia offering closes October 26. Lycia Therapeutics’ upsized initial public offering, priced at 317.5 million dollars for its inflammation and food allergy protein degradation programs and covered in the October 21 story file as updated on October 23, is expected to close today, October 26, 2026. No new pricing or allocation figures were reported in this run’s pool, so the existing file is referenced rather than duplicated.
ESMO closes October 27, Gilead reports October 29. The ESMO Congress in Madrid runs through October 27, 2026. Remaining dated items carried forward from yesterday’s calendar include Zymeworks’ management call on its Roche ZW209 agreement on October 27 at 8:30 AM Eastern, Gilead’s third-quarter results on October 29, and Moderna’s third-quarter results on November 6, 2026. None falls in the morning run’s allowed calendar categories, so no calendar events are proposed from this beat.
Intismeran lung trial design presented today. Moderna presents the design of INTerpath-014, its Phase 3 trial of intismeran in early-stage lung cancer, at ESMO today, October 26, a trials-in-progress presentation with no efficacy data. Yesterday’s edition flagged this presentation; today’s intismeran story covers the melanoma presentation and reaction in full. Source: Moderna ESMO program summary, September 2026, via the October 25 edition.
Women’s heart health framework. Experts presented a framework dividing women’s cardiovascular health into four life stages, in a question and answer with Northwestern cardiologist Sadiya Khan published by STAT on October 26. It is a clinical framework proposal, not trial data or a regulatory action, and it is carried here for completeness rather than as a market item. Source: STAT, October 26, 2026.
US-China biotech deal climate. A Genetic Engineering News StockWatch column on October 25 surveyed investment bankers on United States and Chinese dealmaking, initial public offerings and a difficult fundraising climate for startups. It is opinion and market colour, with no single transaction reported, at a moment when this weekend’s ESMO data, from Akeso, Kelun and Biokin, again showed Chinese-origin assets at the centre of global oncology pipelines. Source: Genetic Engineering News, October 25, 2026.